SCHEMBL10151283

SCHEMBL10151283

COCc1ccccc1COC(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.35
PDK2 Q15119 1/20 0.35
ADRA1A P35348 2/20 0.35
TSHR P16473 2/20 0.33
CASP1 P29466 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
KCNH2 Q12809 1/20 0.33
CACNA1C Q13936 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647871 0.91 IDO1 (0.38) IDO1TSHRMEN1ALDH1A1KMT2A
SCHEMBL648491 0.83 IDO1 (0.44) IDO1PDK2ADRA1ATSHRCASP1
SCHEMBL8750384 0.83 GABRA1 (0.38) IDO1TSHRNPSR1L3MBTL1CACNA1G
SCHEMBL16446710 0.81 KDM4E (0.41) IDO1SMN1; SMN2
SCHEMBL22361574 0.79 L3MBTL1 (0.33) IDO1ADRA1ATSHRALDH1A1NPSR1
SCHEMBL12936623 0.79 IDO1 (0.60) IDO1SMN1; SMN2MEN1ALDH1A1HTT
SCHEMBL12936636 0.78 TAAR1 (0.43) IDO1TSHR
SCHEMBL22391547 0.78 RIPK1 (0.44) IDO1CACNA1GCACNA1HKCNH2CACNA1C
SCHEMBL22957776 0.78 MCL1 (0.42) MEN1ALDH1A1KMT2ACACNA1GCACNA1H
SCHEMBL4979415 0.77 ALDH1A1 (0.38) IDO1PDK2ADRA1ATSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 IDO1 1125/4885PDK2 984/4885ADRA1A 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.